Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2005 2
2007 1
2008 1
2009 2
2010 3
2013 2
2014 1
2015 1
2017 1
2018 3
2019 3
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR, O'Donoghue ML, Papapoulos SE, Bone H, Langdahl B, Saag KG, Reid IR, Kiel DP, Cavallari I, Bonaca MP, Wiviott SD, de Villiers T, Ling X, Lippuner K, Nakamura T, Reginster JY, Rodriguez-Portales JA, Roux C, Zanchetta J, Zerbini CAF, Park JG, Im K, Cange A, Grip LT, Heyden N, DaSilva C, Cohn D, Massaad R, Scott BB, Verbruggen N, Gurner D, Miller DL, Blair ML, Polis AB, Stoch SA, Santora A, Lombardi A, Leung AT, Kaufman KD, Sabatine MS; LOFT Investigators. McClung MR, et al. Lancet Diabetes Endocrinol. 2019 Dec;7(12):899-911. doi: 10.1016/S2213-8587(19)30346-8. Epub 2019 Oct 31. Lancet Diabetes Endocrinol. 2019. PMID: 31676222 Clinical Trial.
Glucocorticoids Decrease Longitudinal Bone Growth in Pediatric Kidney Transplant Recipients by Stimulating the FGF23/FGFR3 Signaling Pathway.
Delucchi Á, Toro L, Alzamora R, Barrientos V, González M, Andaur R, León P, Villanueva F, Galindo M, Las Heras F, Montecino M, Moena D, Lazcano A, Pinto V, Salas P, Reyes ML, Mericq V, Michea L. Delucchi Á, et al. Among authors: gonzalez m. J Bone Miner Res. 2019 Oct;34(10):1851-1861. doi: 10.1002/jbmr.3761. Epub 2019 Aug 26. J Bone Miner Res. 2019. PMID: 31099911 Free article. Clinical Trial.
EVIDENT Smartphone App, a New Method for the Dietary Record: Comparison With a Food Frequency Questionnaire.
Recio-Rodriguez JI, Rodriguez-Martin C, Gonzalez-Sanchez J, Rodriguez-Sanchez E, Martin-Borras C, Martínez-Vizcaino V, Arietaleanizbeaskoa MS, Magdalena-Gonzalez O, Fernandez-Alonso C, Maderuelo-Fernandez JA, Gomez-Marcos MA, Garcia-Ortiz L; EVIDENT Investigators. Recio-Rodriguez JI, et al. Among authors: magdalena gonzalez o. JMIR Mhealth Uhealth. 2019 Feb 8;7(2):e11463. doi: 10.2196/11463. JMIR Mhealth Uhealth. 2019. PMID: 30735141 Free PMC article.
Long-Term Effectiveness of a Smartphone App for Improving Healthy Lifestyles in General Population in Primary Care: Randomized Controlled Trial (Evident II Study).
Garcia-Ortiz L, Recio-Rodriguez JI, Agudo-Conde C, Patino-Alonso MC, Maderuelo-Fernandez JA, Repiso Gento I, Puigdomenech Puig E, Gonzalez-Viejo N, Arietaleanizbeaskoa MS, Schmolling-Guinovart Y, Gomez-Marcos MA, Rodriguez-Sanchez E; EVIDENT Investigators Group; Mobilizing Minds Research Group. Garcia-Ortiz L, et al. JMIR Mhealth Uhealth. 2018 Apr 27;6(4):e107. doi: 10.2196/mhealth.9218. JMIR Mhealth Uhealth. 2018. PMID: 29702473 Free PMC article.
Short- and long-term effectiveness of a smartphone application for improving measures of adiposity: A randomised clinical trial - EVIDENT II study.
Gomez-Marcos MA, Patino-Alonso MC, Recio-Rodriguez JI, Agudo-Conde C, Romaguera-Bosch M, Magdalena-Gonzalez O, Gomez-Arranz A, Mendizabal-Gallastegui N, Angel Fernandez-Diez J, Gomez-Sanchez L, Maderuelo-Fernandez JA, Rodriguez-Sanchez E, Garcia-Ortiz L; on behalf the EVIDENT Investigators 11. Gomez-Marcos MA, et al. Among authors: magdalena gonzalez o. Eur J Cardiovasc Nurs. 2018 Aug;17(6):552-562. doi: 10.1177/1474515118761870. Epub 2018 Feb 28. Eur J Cardiovasc Nurs. 2018. PMID: 29488798 Clinical Trial.
Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury.
Toro L, Barrientos V, León P, Rojas M, Gonzalez M, González-Ibáñez A, Illanes S, Sugikawa K, Abarzúa N, Bascuñán C, Arcos K, Fuentealba C, Tong AM, Elorza AA, Pinto ME, Alzamora R, Romero C, Michea L. Toro L, et al. Among authors: gonzalez m. Kidney Int. 2018 May;93(5):1131-1141. doi: 10.1016/j.kint.2017.11.018. Epub 2018 Feb 1. Kidney Int. 2018. PMID: 29395333 Free article.
27 results